Cargando…

Syndecan-4 as a Marker of Endothelial Dysfunction in Patients with Resistant Hypertension

(1) Background: Arterial hypertension (HTN) is one of the most relevant cardiovascular risk factors. Nowadays multiple pharmaceutical treatment options exist with novel interventional methods (e.g., baroreflex activation therapy (BAT)) as a last resort to treat patients with resistant HTN. Although...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lipphardt, Mark, Dihazi, Hassan, Maas, Jens-Holger, Schäfer, Ann-Kathrin, Amlaz, Saskia I., Ratliff, Brian B., Koziolek, Michael J., Wallbach, Manuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564403/ https://www.ncbi.nlm.nih.gov/pubmed/32971813 http://dx.doi.org/10.3390/jcm9093051

Ejemplares similares

Urinary Dickkopf-3 (DKK3) Is Associated with Greater eGFR Loss in Patients with Resistant Hypertension
por: Schäfer, Ann-Kathrin C., et al.
Publicado: (2023)

Eligibility for Baroreflex Activation Therapy and medication adherence in patients with apparently resistant hypertension
por: Schäfer, Ann‐Kathrin, et al.
Publicado: (2021)

Plasma Exchange or Immunoadsorption in Demyelinating Diseases: A Meta-Analysis
por: Lipphardt, Mark, et al.
Publicado: (2020)

Effect of baroreflex activation therapy on dipping pattern in patients with resistant hypertension
por: Wallbach, Manuel, et al.
Publicado: (2022)

Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic Patients
por: Koziolek, Michael, et al.
Publicado: (2020)

Fibrogenic Secretome of Sirtuin 1-Deficient Endothelial Cells: Wnt, Notch and Glycocalyx Rheostat
por: Lipphardt, Mark, et al.
Publicado: (2018)

Successful baroreflex activation therapy in a case of therapy-resistant renovascular hypertension
por: Nuhn, Eva Maria, et al.
Publicado: (2022)

Impact of medication adherence on the efficacy of Baroreflex activation therapy
por: Schäfer, Ann‐Kathrin C., et al.
Publicado: (2022)

Impact of Elevated LDH on Cystatin C-Based Glomerular Filtration Rate Estimates in Patients with Cancer
por: Aydilek, Enver, et al.
Publicado: (2022)

Thrombin-cleaved syndecan-3/-4 ectodomain fragments mediate endothelial barrier dysfunction
por: Jannaway, Melanie, et al.
Publicado: (2019)

Risk factors for catheter-related infections in patients receiving permanent dialysis catheter
por: Delistefani, Fani, et al.
Publicado: (2019)

Cytokine adsorption therapy in lymphoma-associated hemophagocytic lymphohistiocytosis and allogeneic stem cell transplantation
por: Rademacher, Jan-Gerd, et al.
Publicado: (2021)

Circulating Syndecan-1 and Tissue Factor Pathway Inhibitor, Biomarkers of Endothelial Dysfunction, Predict Mortality in Burn Patients
por: Keyloun, John W., et al.
Publicado: (2021)

Sirtuin 1 and endothelial glycocalyx
por: Lipphardt, Mark, et al.
Publicado: (2020)

Association between syndecan-1 and renal function in adolescents with excess weight: evidence of subclinical kidney disease and endothelial dysfunction
por: Saboia, Z.M.R.M., et al.
Publicado: (2018)

Contribution of syndecan-4 genetic variants to hypertension, the TAMRISK study
por: Kunnas, Tarja, et al.
Publicado: (2014)

miR-19b targets pulmonary endothelial syndecan-1 following hemorrhagic shock
por: Wu, Feng, et al.
Publicado: (2020)

Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells
por: Lamorte, S, et al.
Publicado: (2012)

Syndecan-4 is More Sensitive in Detecting Hypertensive Left Ventricular Diastolic Dysfunction in 2K2C Rats
por: Dai, Wenyue, et al.
Publicado: (2022)

Yellow fever disease severity and endothelial dysfunction are associated with elevated serum levels of viral NS1 protein and syndecan-1
por: de Sousa, Francielle T. G., et al.
Publicado: (2023)

Serum syndecan-1 reflects organ dysfunction in critically ill patients
por: Suzuki, Keiko, et al.
Publicado: (2021)

Syndecan-3 and syndecan-4 are enriched in Schwann cell perinodal processes
por: Goutebroze, Laurence, et al.
Publicado: (2003)

Flow-Mediated Dilation, a Marker of Endothelial Cell Dysfunction, in Patients with Pulmonary Hypertension
por: Mirdamadi, Ahmad, et al.
Publicado: (2021)

Syndecan-3 and TFPI Colocalize on the Surface of Endothelial-, Smooth Muscle-, and Cancer Cells
por: Tinholt, Mari, et al.
Publicado: (2015)

Acquisition of Anoikis Resistance Up-Regulates Syndecan-4 Expression in Endothelial Cells
por: Carneiro, Bruna Ribeiro, et al.
Publicado: (2014)

Possible involvement of Syndecan-1 in the state of COVID-19 related to endothelial injury
por: Suzuki, Keiko, et al.
Publicado: (2021)

Syndecan-1 downregulates syndecan-4 expression by suppressing the ERK1/2 and p38 MAPK signaling pathways in cultured vascular endothelial cells
por: Hara, Takato, et al.
Publicado: (2021)

Endothelial progenitor cells (EPC) in sepsis with acute renal dysfunction (ARD)
por: Patschan, Susann A, et al.
Publicado: (2011)

Is Syndecan-2 a Key Angiogenic Element?
por: Noguer, Oriol, et al.
Publicado: (2009)

Syndecan‐4, a model proteoglycan to study endothelial glycocalyx mechanosensing and signal transduction
por: van den Berg, Bernard M.
Publicado: (2019)

Syndecan-4 functionalization of tissue regeneration scaffolds improves interaction with endothelial progenitor cells
por: Warner, Harleigh, et al.
Publicado: (2021)

Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis
por: Koziolek, Michael J, et al.
Publicado: (2012)

The association between endothelial dysfunction and hypertensive retinopathy in essential hypertension
por: Karaca, Mustafa, et al.
Publicado: (2014)

High Preoperative Serum Syndecan-1, a Marker of Endothelial Glycocalyx Degradation, and Severe Acute Kidney Injury after Valvular Heart Surgery
por: Kim, Hye-Bin, et al.
Publicado: (2020)

Vascular Inflammation and Endothelial Dysfunction in Experimental Hypertension
por: Savoia, Carmine, et al.
Publicado: (2011)

Mechanisms of endothelial dysfunction in obesity-associated hypertension
por: Lobato, N.S., et al.
Publicado: (2012)

Contribution of oxidative stress to endothelial dysfunction in hypertension
por: Silva, Bruno R., et al.
Publicado: (2012)

Role of MicroRNA in Endothelial Dysfunction and Hypertension
por: Nemecz, Miruna, et al.
Publicado: (2016)

Endothelial Dysfunction in Pulmonary Hypertension: Cause or Consequence?
por: Kurakula, Kondababu, et al.
Publicado: (2021)

Syndecan-Regulated Receptor Signaling
por: Rapraeger, Alan C.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_9fphipd917cnvjveno3enjvv6s